We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

Back to rankings

37 hedge funds and large institutions have $61.9M invested in Constellation Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

6% more funds holding

Funds holding: 35 → 37 (+2)

15% less capital invested

Capital invested by funds: $73M → $61.9M (-$11.1M)

Holders
37
Holders Change
+2
Holders Change %
+5.71%
% of All Funds
0.82%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
8
Increased
10
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$1.46M
2
First Eagle Investment Management
First Eagle Investment Management
New York
+$754K
3
SFM
Sphera Funds Management
Israel
+$423K
4
JRP
Jasper Ridge Partners
California
+$372K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$162K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$1.21M
2
Victory Capital Management
Victory Capital Management
Texas
-$957K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$525K
4
BlackRock
BlackRock
New York
-$502K
5
DIM
DC Investments Management
Virginia
-$351K
Name Holding Trade Value Shares
Change 		Change in
Stake
PS
1
Peter Svennilson
$18.8M +$28.2M +4,677,938 New
TG
2
TRV GP
Massachusetts
$12.2M – – –
CC
3
Casdin Capital
New York
$6.24M +$1.46M +242,255 +18%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.13M -$266K -44,100 -3%
CAM
5
Cormorant Asset Management
Massachusetts
$5.1M – – –
O
6
OrbiMed
New York
$3.35M – – –
VMI
7
VHCP Management II
New York
$2.91M – – –
DM
8
Deerfield Management
New York
$2.55M – – –
HIM
9
Hillhouse Investment Management
Cayman Islands
$1.27M – – –
BBA
10
Baker Bros. Advisors
New York
$535K – – –
First Eagle Investment Management
11
First Eagle Investment Management
New York
$501K +$754K +125,000 New
BlackRock
12
BlackRock
New York
$427K -$502K -83,179 -44%
EC
13
EcoR1 Capital
California
$318K -$1.21M -200,806 -72%
SFM
14
Sphera Funds Management
Israel
$281K +$423K +70,162 New
VMI
15
VHCP Management III
New York
$267K – – –
JRP
16
Jasper Ridge Partners
California
$247K +$372K +61,643 New
Vanguard Group
17
Vanguard Group
Pennsylvania
$240K -$525K -87,054 -59%
Northern Trust
18
Northern Trust
Illinois
$204K +$33.9K +5,624 +12%
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$108K +$162K +26,919 New
State Street
20
State Street
Massachusetts
$68K +$102K +16,894 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$55K +$12K +1,987 +17%
Morgan Stanley
22
Morgan Stanley
New York
$36K +$898 +149 +2%
California State Teachers Retirement System (CalSTRS)
23
California State Teachers Retirement System (CalSTRS)
California
$24K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$21K -$28.7K -4,768 -47%
Bank of America
25
Bank of America
North Carolina
$17K +$19.9K +3,298 +325%
1
2

CNST Hedge Fund Activity: Q4 2018 in Review

37 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q4 2018, worth a combined $61.9M — down 15% from $73M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CNST positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 8 trimmed.

The largest buyer was Casdin Capital, adding an estimated $1.46M. The largest seller was EcoR1 Capital, cutting an estimated $1.21M.

  • 37 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q4 2018, up from 35 in Q3 2018.
  • Funds reported $61.9M of Constellation Pharmaceuticals, Inc. stock for Q4 2018, down 15% quarter-over-quarter.
  • 8 funds opened new Constellation Pharmaceuticals, Inc. positions in Q4 2018 and 6 closed out, a net change of +2 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q4 2018 was Casdin Capital, an estimated $1.46M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q4 2018 was EcoR1 Capital, an estimated $1.21M sold.

Based on aggregated 13F filings for Q4 2018.